Search
Malacidin A
go.drugbank.com/drugs/DB14051ExperimentalMalacidin A, along with DB14052, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic ...
Temoporfin
go.drugbank.com/drugs/DB11630ApprovedIt was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.
Laromustine
go.drugbank.com/drugs/DB05817InvestigationalVNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]
Amrubicin
go.drugbank.com/drugs/DB06263InvestigationalIn 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer
CNS-5161
go.drugbank.com/drugs/DB05824ExperimentalCNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
T487
go.drugbank.com/drugs/DB05474ExperimentalThe formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Chlorine
go.drugbank.com/drugs/DB11109ApprovedInvestigationalIt was also used in chemical warfare and in rocket fuel. … Being a yellow-green gas at room temperature, chlorine is the second most abundant halogen on Earth. It is commonly used in sanitation, disinfection and antiseptic processes.
S-8510
go.drugbank.com/drugs/DB06504ExperimentalIt was being codeveloped by Shionogi and GlaxoSmithKline.
Clesrovimab
go.drugbank.com/drugs/DB18877Approvedto provide passive immunization against RSV infection as an alternative means of protection. … [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233]